United States Autoimmune Disease Diagnostics Market to Grow with a CAGR of 7.08% through 2028
Rising disease prevalence, government initiatives, and
an expanding product portfolio is expected to drive the United States Autoimmune
Disease Diagnostics Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “United States Autoimmune Disease Diagnostics
Market – By Region, Competition, Forecast and Opportunities, 2028”, the United
States Autoimmune Disease Diagnostics Market stood at USD 1.36 billion in 2022
and is anticipated to grow with a CAGR of 7.08% in the forecast period,
2024-2028. This can be attributed to collaborations and mergers. Collaboration
and mergers within the healthcare sector have also contributed to market
growth. Companies often join forces to combine expertise, share resources, and
develop more comprehensive diagnostic solutions. These collaborations enable
the creation of innovative diagnostics that can address the complexity of
autoimmune diseases effectively.
Moreover, patient-centric diagnostics prioritize the
patient's experience and preferences. This trend emphasizes communication,
education, and shared decision-making between patients and healthcare
providers. Autoimmune disease diagnostics are evolving to involve patients in
the diagnostic process, leading to more informed decisions and improved
adherence to treatment plans.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "United States Autoimmune Disease Diagnostics Market.”
The market is being driven by factors such as the
increasing prevalence of autoimmune diseases, heightened awareness regarding
disease diagnosis, and advancements in technology. The rising incidence of
autoimmune disorders is expected to boost the growth of the autoimmune disease
diagnostics market. According to the 2020 Atlas of Multiple Sclerosis Report,
over 2.8 million people worldwide, with approximately 1 million in the United
States, are currently living with multiple sclerosis. Europe faced a significant
burden of autoimmune diseases, with the highest prevalence of multiple
sclerosis in 2020, estimated at 2.5 million people globally. Rheumatoid
arthritis affects around two million people, and psoriasis, one of the most
common autoimmune disorders, is believed to impact between 2% and 3% of the
general population. Increased awareness of autoimmune disorders through
research, education, support, and advocacy initiatives is a significant driver
of rising diagnosis rates.
Furthermore, the escalating global burden of
autoimmune diseases, along with increasing health and disease awareness, fuels
the demand for early disease detection diagnostics, driving market growth. For
example, the American Autoimmune Related Disease Association (AARDA) designates
March as Autoimmune Disease Awareness Month (ADAM) to raise awareness and
support the eradication of autoimmune diseases. The American Kidney Fund (AKF)
launched an educational campaign in February 2021 focused on lupus nephritis, a
kidney condition caused by lupus, providing crucial information to patients
about symptoms, diagnosis, and treatment. In September 2021, Scipher Medicine
partnered with Ventegra Inc. to offer customers access to Scipher's PrismRA
liquid molecular signature test, aiding in the personalized treatment of
rheumatoid arthritis patients (RA). Despite these promising factors, challenges
such as delayed result turnaround, the necessity for multiple diagnostic tests,
high costs, reimbursement concerns, and regulatory uncertainties may hinder
market growth.
The United States Autoimmune Disease Diagnostics
Market is segmented into component, test type, disease type, end user, regional
distribution, and company.
Based on end user, hospitals and clinics are poised to
dominate the United States autoimmune disease diagnostics market due to their
pivotal role in healthcare infrastructure. These healthcare facilities serve as
primary points of care for patients seeking diagnosis and treatment. With the
increasing prevalence of autoimmune diseases and the need for accurate and
timely diagnostics, hospitals and clinics become central hubs for autoimmune
disease testing. They offer a wide range of diagnostic services, access to
specialized medical professionals, and state-of-the-art equipment necessary for
comprehensive autoimmune disease diagnosis. Moreover, the trend toward
collaborative and multidisciplinary approaches to healthcare further solidifies
the position of hospitals and clinics as key players in the autoimmune disease
diagnostics market, as they provide integrated care and access to a wide array
of diagnostic tools, including advanced imaging, genetic testing, and
biomarker-based assays, essential for accurate diagnosis and effective disease
management.
Based on region, the North-East region is primed to
dominate the United States Autoimmune Disease Diagnostics market due to several
compelling factors. Firstly, it hosts some of the nation's most prestigious
academic and medical institutions, such as Harvard, MIT, and Johns Hopkins,
which serve as hotbeds for cutting-edge research and innovation in healthcare.
These institutions attract top talent, leading to a concentration of experts in
autoimmune disease diagnostics. Furthermore, the North-East's dense population
centers, including major cities like Boston, New York, and Philadelphia, offer
a diverse patient demographic, driving demand for advanced diagnostics and
increasing the market's potential. Additionally, the region's robust healthcare
policies and insurance coverage ensure that patients have access to
state-of-the-art diagnostic technologies and services. The North-East's
well-established biotechnology and pharmaceutical industry also fosters
collaboration and investment in autoimmune disease diagnostics, positioning the
region as a frontrunner in this crucial sector of healthcare innovation.
Major companies operating in United
States Autoimmune Disease Diagnostics Market are:
- Abbott Laboratories
- Siemens Healthineers AG
- Roche Diagnostics Corp
- Beckman Coulter Inc
- SQI Diagnostics Inc
- EUROIMMUN Medizinische
Labordiagnostika AG
- Aesku Diagnostics GmbH & Co KG
- INOVA Diagnostics Inc
- Crescendo Bioscience LLC
- bioMerieux SA
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The United States Autoimmune Disease Diagnostics
Market is witnessing a transformation driven by emerging trends that focus on
precision medicine, biomarker discovery, point-of-care testing, artificial
intelligence, telemedicine, multiplex testing, patient-centric diagnostics,
global expansion, and ongoing research and development. These trends hold the
promise of improving the accuracy, accessibility, and personalization of
autoimmune disease diagnostics, ultimately enhancing patient care and outcomes.
As technology continues to advance and the understanding of autoimmune diseases
deepens, the future of autoimmune disease diagnostics appears promising, offering
hope for better disease management and improved quality of life for patients,”
said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based management consulting firm.
“United
States Autoimmune
Disease Diagnostics Market By
Component (Instruments, Reagents, Consumables), By
Test Type (Routine Laboratory Tests, Inflammatory Markers, Antibodies &
Immunologic Tests, Others), By Disease Type (Systemic Autoimmune Disease
Diagnostics, Localized Autoimmune Disease Diagnostics) By Systemic Autoimmune
Diseases (Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus
Erythematosus, Others), By Localized Autoimmune Diseases (Multiple Sclerosis,
Type 1 Diabetes, Hashimoto’s Thyroiditis, Others), By End User (Hospitals &
Clinics, Diagnostic Centers, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of United States Autoimmune Disease Diagnostics
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in United States Autoimmune
Disease Diagnostics Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com